Marex Group plc to announce fourth quarter and full year 2025 results on March 3, 2026 with an Investor Day on March 26, 2026
Marex Group plc (NASDAQ: MRX) announced it will release its fiscal 2025 fourth quarter and full year results before market open on Tuesday, March 3, 2026. A conference call will be held on the same day at 9 AM ET to discuss these results. Additionally, Marex will host an investor day on Thursday, March 26, 2026, in New York.
Marex Group plc to Announce Fiscal 2025 Fourth Quarter and Full Year Results on March 3, 2026
Marex Group plc (NASDAQ: MRX) will announce its fiscal 2025 fourth quarter and full year results on March 3, 2026, before market open, followed by a conference call at 9 AM ET the same day. The company, a global financial services platform, also plans an investor day on March 26, 2026, in New York. Analysts and hedge funds have shown interest in MRX stock, with positive ratings and varying institutional portfolio adjustments.
Marex Group plc to Announce Fiscal 2025 Fourth Quarter and Full Year Results on March 3, 2026
Marex Group plc announced it will release its fiscal 2025 fourth quarter and full year results on March 3, 2026, followed by an investor conference call at 9 AM ET. The company will also host an investor day in New York on March 26, 2026. Marex Group is a global financial services platform offering liquidity, market access, and infrastructure across various financial markets.
Marex Group plc to announce fourth quarter and full year 2025 results on March 3, 2026 with an Investor Day on March 26, 2026
Marex Group plc (NASDAQ: MRX) announced it will release its fiscal 2025 fourth quarter and full year results before market open on Tuesday, March 3, 2026, with a conference call scheduled for 9 am ET the same day. The company will also host an investor day in New York on Thursday, March 26, 2026. Marex is a diversified global financial services platform providing liquidity, market access, and infrastructure services across various markets.
Marex Group plc to announce fourth quarter and full year
Marex Group plc announced it will release its fiscal 2025 fourth quarter and full year results on March 3, 2026, before market open. The company will also hold an investor day in New York on March 26, 2026. Marex is a diversified global financial services platform operating across energy, commodities, and financial markets.
Marex Group stock hits 52-week high at 40.48 USD By Investing.com
Marex Group (MRX) stock reached a new 52-week high of $40.48, reflecting a 12.03% increase over the past year and a 15.3% return over the last six months. The company, with a market capitalization of $2.9 billion and a PEG ratio of 0.38, shows strong financial health and investor confidence despite appearing slightly overvalued. Marex is also expanding its market presence through strategic acquisitions, including Webb Traders and potential acquisition of Levmet.
Marex Group stock hits 52-week high at 40.48 USD
Marex Group PLC's stock reached a new 52-week high of $40.48, reflecting a 12.03% increase over the past year and a 15.3% return over six months. The company, with a market capitalization of $2.9 billion and a PEG ratio of 0.38, shows strong financial health and investor confidence despite appearing slightly overvalued. Marex is also expanding through strategic acquisitions, including Webb Traders and potential talks with Levmet.
Marex to acquire European equity derivatives market maker Webb Traders By Investing.com
Marex Group plc has announced its agreement to acquire Webb Traders, a European equity derivatives market maker specializing in single stock options. This acquisition aims to enhance Marex's Equity Linked Structured Products platform, improve profit margins through internalized hedging, and offer better client pricing. The deal is subject to regulatory approval and is expected to finalize in the second or third quarter of 2026, building on Marex's strategy for growth and expansion.
Marex Group plc to acquire equity derivatives market maker Webb Traders
Marex (NASDAQ: MRX) has announced its agreement to acquire European equity derivatives market maker Webb Traders, aiming to enhance its market-making capabilities and structured products platform. The acquisition will bring specialized teams in Amsterdam and Paris focusing on single-stock options and is expected to internalize hedging, improve pricing, and boost profit margins. This move continues Marex's strategy of targeted acquisitions to broaden its multi-asset financial services offering, with the deal anticipated to close in Q2 or Q3 2026, subject to regulatory approval.
Marex to acquire European equity derivatives market maker Webb Traders
Marex Group plc has announced its agreement to acquire Webb Traders, a European equity derivatives market maker. This acquisition is expected to enhance Marex's Equity Linked Structured Products platform, improve profit margins by internalizing hedging, and provide better pricing for clients. The deal is subject to regulatory approval and is anticipated to close in the second or third quarter of 2026.
Marex to acquire equity derivatives market maker Webb Traders
Global financial services platform Marex Group plc announced its agreement to acquire European equity derivatives market maker Webb Traders. This acquisition is set to enhance Marex's market making capabilities, specifically in single stock options for European and US equities, by integrating Webb Traders' technology and team. The deal, which aims to improve hedging internalisation, profit margins, and client pricing, awaits regulatory approval and is expected to close in Q2 or Q3 of 2026.
Marex Group plc to acquire equity derivatives market maker Webb Traders
Marex Group plc announced its agreement to acquire Webb Traders, a European equity derivatives market maker specializing in single-stock options. This acquisition aims to enhance Marex's market-making capabilities and equity-linked structured products platform by integrating Webb Traders' technology-led team and electronic trading expertise. The deal, which aligns with Marex's risk management philosophy, is expected to close in the second or third quarter of 2026, subject to regulatory approval.
Marex Group plc to acquire equity derivatives market maker Webb Traders
Marex Group plc announced its agreement to acquire Webb Traders, a European equity derivatives market maker specializing in single stock options. This acquisition is expected to enhance Marex's market making capabilities, internalize hedging, improve profit margins, and offer better pricing to clients. The deal is subject to regulatory approval and is anticipated to close in the second or third quarter of 2026.
Assessing Marex Group (MRX) Valuation After Recent Share Price Momentum
This article analyzes Marex Group (MRX) stock performance and valuation, noting its recent share price momentum and positive returns over the past month and three months. Simply Wall St's analysis suggests MRX is undervalued with a fair value of $50.29, compared to its trading price of $40.48. The narrative supporting this valuation hinges on rising profitability, a richer earnings multiple, and anticipated earnings growth, though risks like acquisition integration and a class action lawsuit are also highlighted.
Assessing Marex Group (MRX) Valuation After Upbeat Analyst Earnings Revisions
Analyst reports on Marex Group (MRX) show increased optimism regarding its earnings outlook, leading to revised forecasts and positive ratings. The stock has seen significant momentum with a 32.28% 90-day return and a 21.80% annual total shareholder return. Despite trading at a reported 4.2% intrinsic discount, simply Wall St's analysis suggests a fair value of $47.71 due to productivity gains and operating leverage, indicating it is undervalued.
Marex Group (MRX) Is Up 6.1% After Analyst Upgrades Highlight Its Diversified Earnings Engine
Marex Group (MRX) has seen its stock rise by 6.1% following increased attention from analysts who have raised earnings estimates and reinforced positive ratings. This comes as Marex's diversified operations and profit generation are gaining recognition despite previous under-coverage. While analysts are optimistic, the article also notes the company faces legal and regulatory scrutiny regarding prior alleged misstatements, which could impact its growth narrative.
Are You Looking for a Top Momentum Pick? Why Marex Group PLC (MRX) is a Great Choice
Marex Group PLC (MRX) is identified as a strong momentum pick due to its B score on the Zacks Momentum Style Score and a Zacks Rank #2 (Buy). The article highlights MRX's impressive short-term and longer-term price activity, outperforming its industry and the S&P 500, along with favorable earnings estimate revisions. Investors looking for stocks with strong near-term potential are encouraged to consider MRX.
Wall Street Analysts See a 28.45% Upside in Marex Group PLC (MRX): Can the Stock Really Move This High?
Wall Street analysts project a potential 28.5% upside for Marex Group PLC (MRX), with a mean price target of $50.29. While analysts' price targets can be misleading due to inherent biases, strong agreement on upward earnings estimate revisions and a Zacks Rank #2 (Buy) suggest a legitimate potential for appreciation in the stock's value. Investors are advised to view price targets with skepticism but consider the confluence of positive indicators for MRX.
Marex Group plc (MRX): A Bull Case Theory
This article summarizes a bullish thesis on Marex Group plc (MRX), a UK-based global financial services platform. The thesis, from MOI Global Equity Research, highlights Marex's strong market position due to high barriers to entry, industry consolidation, and favorable secular and cyclical tailwinds. Despite a recent stock price decrease, the article suggests Marex is undervalued given its consistent profit growth and strategic growth initiatives.
Wall Street Analysts See a 28.45% Upside in Marex Group PLC (MRX): Can the Stock Really Move This High?
Shares of Marex Group PLC (MRX) have gained 1.2% recently, and Wall Street analysts project a potential upside of 28.5%, with a mean estimate of $50.29. While price targets are viewed with skepticism by some researchers, a positive trend in earnings estimate revisions and a Zacks Rank #2 (Buy) suggest a legitimate reason for optimism regarding the stock's near-term upside. Investors are advised to treat price targets with caution but consider the strong correlation between earnings estimate revisions and stock price movements.
Marex Group (MRX) Analyst Rating Update: Barclays Lowers Price T
Barclays has reiterated its 'Overweight' rating for Marex Group (MRX) but has adjusted its price target down from $50 to $49, a 2.00% decrease. This change was noted by analyst Benjamin Budish on January 8, 2026. Despite the slight reduction in the price target, the average target price from 7 analysts remains $48.57, suggesting a 26.92% upside from the current price.
Marex Is Growing Fast, Yet Trading Like A Bargain
Marex Group plc exhibits strong profit growth and high returns on equity yet trades at a significant discount compared to its financial-services peers, reflecting investor concerns about cyclical revenue and regulatory pressures. The company's expansion in prime services and geographical diversification are key growth drivers, with analysts forecasting a 28% upside to its consensus price target. Despite risks like market volatility and integration challenges, Marex's robust balance sheet and consistent management track record suggest it could be an attractive opportunity for long-term investors in specialty financial services.
Marex Group (MRX): Assessing Valuation After a 20% One-Month Share Price Surge
Marex Group (MRX) experienced a 20% share price surge in the past month, leading to questions about its current valuation. While a narrative suggests it's 17.9% undervalued with a fair value of $47.70 due to productivity gains and margin expansion, Simply Wall St's DCF model pegs a fair value closer to $38.73, suggesting it's currently trading near fair value. Investors are encouraged to assess the risks and potential upsides through their own analysis.
Marex Group plc Makes New Investment in Lumentum Holdings Inc. $LITE
Marex Group plc has made a new investment in Lumentum Holdings Inc. (NASDAQ:LITE), acquiring 3,022 shares valued at approximately $287,000. Institutional investors now own 94.05% of Lumentum, which recently beat earnings expectations and provided strong Q2 2026 guidance. Despite insider selling, analysts rate the stock a "Moderate Buy" with an average price target of $215.00.
Marex Group plc Makes New Investment in Coupang, Inc. $CPNG
Marex Group plc recently acquired a new stake in Coupang, Inc. (NYSE:CPNG), purchasing 51,549 shares valued at approximately $1.54 million. Coupang reported strong Q2 earnings, beating estimates with $0.05 EPS and achieving $9.27 billion in revenue, an increase of 17.8% year-over-year. Institutional investors hold a significant portion of the stock, while analysts maintain a "Moderate Buy" consensus with a $33.88 target price.
Marex Group plc Makes New Investment in Futu Holdings Limited Sponsored ADR $FUTU
Marex Group plc has acquired a new stake in Futu Holdings Limited, purchasing 12,541 shares valued at approximately $1.55 million. This investment follows Futu's strong Q3 results, which saw EPS of $2.93 and revenue of $822.8 million, exceeding analyst expectations. Analysts maintain a generally positive outlook on Futu, with an average "Buy" rating and a price target of $203.67.
Marex Group plc Acquires Shares of 14,493 Macro Bank Inc. $BMA
Marex Group plc initiated a new position in Macro Bank (NYSE: BMA) by purchasing 14,493 shares valued at approximately $1.02 million. This comes as several institutional investors have adjusted their holdings and multiple analysts have upgraded coverage and raised price targets for Macro Bank. Despite beating revenue estimates, the bank missed on quarterly EPS and has a high dividend payout ratio of 189.14%, raising potential sustainability concerns.
Marex Group plc Purchases New Stake in MercadoLibre, Inc. $MELI
Marex Group plc has acquired a new stake in MercadoLibre, Inc. (NASDAQ:MELI) totaling 3,793 shares, valued at approximately $9.91 million. This comes as institutional ownership in MercadoLibre stands at 87.62%, despite recent insider selling by two directors. The company recently missed EPS estimates but exceeded revenue expectations, and analysts currently hold a "Moderate Buy" rating for the stock with a consensus price target near $2,849.
Marex Group plc Takes $6.76 Million Position in Quantum Computing Inc. $QUBT
Marex Group plc has acquired a new position in Quantum Computing Inc. (NASDAQ:QUBT), purchasing 352,607 shares valued at approximately $6.76 million, representing 0.22% of the company. Analyst sentiment for QUBT is mixed, averaging to a "Hold" rating with an average target price of $23.67, despite a director selling shares recently. Quantum Computing's stock opened at $12.05, with institutional investors owning 4.26% and insiders 19.30% of the company.
Marex Group plc Buys Shares of 24,300 Astera Labs, Inc. $ALAB
Marex Group plc has initiated a new position in Astera Labs, Inc. by purchasing 24,300 shares valued at approximately $2.197 million during the second quarter. Despite recent insider selling, Astera Labs exceeded its quarterly earnings estimates, reporting $0.49 EPS against an expected $0.39 and revenue of $230.6 million, a 103.9% year-over-year increase. The company currently holds a "Moderate Buy" consensus rating with a target price of $188.17.
Marex Group plc Invests $53.63 Million in Hims & Hers Health, Inc. $HIMS
Marex Group plc recently acquired 1,081,476 shares of Hims & Hers Health, Inc. (NYSE: HIMS) totaling approximately $53.63 million, making it their 10th largest holding. Despite this institutional investment, company insiders have been net sellers, with CEO Andrew Dudum and other insiders selling shares worth millions. Hims & Hers reported mixed financial results, missing EPS estimates but exceeding revenue expectations, and announced a $250 million share buyback program.
Marex Group plc Makes New $74.36 Million Investment in Rocket Lab Corporation $RKLB
Marex Group plc has made a new $74.36 million investment in Rocket Lab Corporation (NASDAQ:RKLB), acquiring 2,078,807 shares. This new position makes Rocket Lab Marex Group's 7th largest holding, representing 0.6% of its investment portfolio. Other major institutions have also built significant stakes, with hedge funds and institutional investors now owning 71.78% of the stock.
Barclays Sticks to Its Buy Rating for Marex Group plc (MRX)
Barclays analyst Benjamin Budish maintained a Buy rating for Marex Group plc (MRX) with a price target of $50.00. This recommendation comes despite a year-over-year decrease in the company's Q2 revenue and net profit. The broader analyst consensus for Marex Group plc is a Strong Buy, with an average price target of $51.17.
Marex Group plc Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before December 8, 2025 to Discuss Your Rights - MRX
The Gross Law Firm has issued a notice to shareholders of Marex Group plc (NASDAQ: MRX) regarding a class action lawsuit alleging securities law violations. The lawsuit claims Marex Group plc made false statements and concealed that it improperly inflated its cash flow, revenues, assets, and profits of its Market Making segment through off-book intercompany transactions. Investors who purchased MRX shares between May 16, 2024, and August 5, 2025, are encouraged to contact the law firm before the December 8, 2025 deadline to discuss their rights and possible lead plaintiff appointment.
Barclays Sticks to Its Buy Rating for Marex Group plc (MRX)
Barclays analyst Benjamin Budish maintained a Buy rating on Marex Group plc (MRX) with a $50.00 price target. This rating aligns with a Street consensus of Strong Buy for MRX, which has an average price target of $51.17. The report follows the company's latest earnings, revealing a quarterly revenue of $500.1 million and a net profit of $76.7 million.
Shareholders of Marex Group plc Should Contact The Gross Law Firm Before December 8, 2025 to Discuss Your Rights – MRX
The Gross Law Firm is notifying shareholders of Marex Group plc (NASDAQ: MRX) about a class action lawsuit. Investors who purchased MRX shares between May 16, 2024, and August 5, 2025, are encouraged to contact the firm regarding their rights before the lead plaintiff deadline of December 8, 2025. The lawsuit alleges that Marex Group plc materially misrepresented its cash flow, revenues, assets, and profits in its Market Making segment through undisclosed intercompany transactions.
MRX DEADLINE - FINAL REMINDER: Bronstein, Gewirtz & Grossman LLC Alerts Marex Group plc.. Investors to Participate in the Class Action Lawsuit
Bronstein, Gewirtz & Grossman, LLC has issued a final reminder for investors of Marex Group plc (NASDAQ: MRX) to participate in a class action lawsuit. The lawsuit alleges that Marex made materially false and misleading statements and failed to disclose conflicts of interest related to selling over-the-counter financial products to itself, leading to unreliable financial statements. Investors who suffered losses and purchased shares between May 16, 2024, and August 5, 2025, have until December 8, 2025, to request to be appointed as lead plaintiff.
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Marex Group
Faruqi & Faruqi, LLP is investigating potential securities fraud claims against Marex Group plc (NASDAQ: MRX) on behalf of investors who purchased securities between May 16, 2024, and August 5, 2025. The investigation follows a report by NINGI Research alleging a multi-year accounting scheme by Marex, leading to a significant stock drop. Investors have until December 8, 2025, to seek the role of lead plaintiff in the federal securities class action.
Do Marex Group’s (MRX) Accounting Allegations Raise Deeper Questions About Its Governance And Controls?
Several U.S. law firms have launched securities class actions against Marex Group plc, alleging self-dealing over-the-counter trades and unreliable financial statements between May 16, 2024, and August 5, 2025. These allegations of inflated cash flows and revenues through off-book intercompany transactions raise concerns about Marex's governance and financial reporting controls. The ongoing legal issues will impact Marex's investment narrative, particularly its structured products business expansion, by affecting client, counterparty, and regulatory reactions.
Class Action Reminder from Pomerantz LLP for Shareholders of Marex Group Plc – MRX
Pomerantz LLP has filed a class action lawsuit against Marex Group Plc (NASDAQ:MRX) for alleged securities fraud, following a report by NINGI Research claiming the company engaged in an accounting scheme to conceal losses and inflate profits. Investors who purchased Marex securities during the Class Period have until December 8, 2025, to seek appointment as Lead Plaintiff. The lawsuit was prompted by a significant drop in Marex's stock price after the NINGI Research report was published.
Do Marex Group’s (MRX) Accounting Allegations Raise Deeper Questions About Its Governance And Controls?
Recent securities class actions allege Marex Group engaged in self-dealing over-the-counter trades and issued unreliable financial statements, specifically inflating cash flows, revenues, assets, and profits in its Market Making segment through off-book intercompany transactions. These allegations raise concerns about the company's governance and financial reporting controls, impacting its investment narrative and the future success of its structured products business expansion. Investors are urged to consider how these legal and governance issues could affect Marex's reputation, earnings sustainability, and expansion plans.
Shareholders of Marex Group plc Should Contact The Gross Law Firm Before December 8, 2025 to Discuss Your Rights – MRX
The Gross Law Firm is encouraging shareholders of Marex Group plc (NASDAQ: MRX) who bought shares between May 16, 2024, and August 5, 2025, to contact them regarding a class action lawsuit. The lawsuit alleges that Marex improperly inflated its cash flow, revenues, assets, and profits of its Market Making segment through off-book intercompany transactions, leading to false and misleading statements about the company's business. Shareholders have until December 8, 2025, to register their information to potentially be appointed as a lead plaintiff.
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Marex Group
Faruqi & Faruqi, LLP is investigating potential securities claims against Marex Group plc (NASDAQ: MRX) on behalf of investors. The firm announced a reminder of the upcoming December 8, 2025 deadline for investors to seek lead plaintiff status in a federal securities class action lawsuit. The lawsuit alleges that Marex made false and misleading statements and concealed an accounting scheme involving off-balance-sheet entities and fictitious transactions, which led to a stock drop after a report by NINGI Research.
Shareholders of Marex Group plc Should Contact The Gross
The Gross Law Firm has issued a notice for shareholders of Marex Group plc (NASDAQ: MRX) encouraging them to contact the firm regarding a potential lead plaintiff appointment. This follows allegations that the company made false statements and concealed the improper inflation of its cash flow and market-making segment revenues through off-book intercompany transactions. The deadline to register for this class action and seek lead plaintiff status is December 8, 2025.
Marex Group plc Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before December 8, 2025 to Discuss Your Rights - MRX
The Gross Law Firm has issued a notice to shareholders of Marex Group plc (NASDAQ: MRX) regarding a class action lawsuit. The lawsuit alleges that Marex Group plc made false statements and concealed that it improperly inflated its cash flow, revenues, assets, and profits of its Market Making segment through off-book intercompany transactions between May 16, 2024, and August 5, 2025. Investors who purchased shares during this period are encouraged to contact the firm before the December 8, 2025 deadline to discuss their rights and potential lead plaintiff appointment.
Portnoy Law Firm Announces Class Action on Behalf of Marex Group plc. Investors
The Portnoy Law Firm has announced a class action lawsuit against Marex Group plc (NASDAQ: MRX) on behalf of investors who purchased securities between May 16, 2024, and August 5, 2025. This action follows a report by NINGI Research alleging Marex engaged in an accounting scheme involving off-balance-sheet entities and misleading disclosures, which caused Marex's stock price to fall. Investors have until December 8, 2025, to file a lead plaintiff motion.
Portnoy Law Firm Announces Class Action on Behalf of Marex Group plc. Investors
The Portnoy Law Firm has announced a class action lawsuit on behalf of investors in Marex Group plc (NASDAQ: MRX) who purchased securities between May 16, 2024, and August 5, 2025. This action follows a report by NINGI Research alleging Marex engaged in an accounting scheme to conceal losses and inflate profits. Investors have until December 8, 2025, to file a lead plaintiff motion.
MRX Investors Have Opportunity to Lead Marex Group plc Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm has announced a class action lawsuit against Marex Group plc (NASDAQ: MRX) for alleged securities fraud, urging investors who purchased shares between May 16, 2024, and August 5, 2025, to join before December 8, 2025. The lawsuit claims Marex made false and misleading statements, including selling over-the-counter financial products to itself and having unreliable financial statements due to inconsistencies between subsidiaries and related parties, causing investor damages.
MRX Deadline: MRX Investors with Losses in Excess of $100K Have Opportunity to Lead Marex Group plc Securities Fraud Lawsuit
The Rosen Law Firm is reminding investors of Marex Group plc (NASDAQ: MRX) who incurred losses exceeding $100,000 during the Class Period (May 16, 2024, to August 5, 2025) about the upcoming lead plaintiff deadline on December 8, 2025. The class action lawsuit alleges that Marex made materially false and misleading statements, particularly concerning its financial statements and internal transactions. Investors are encouraged to contact the Rosen Law Firm to join the lawsuit and potentially recover damages.
Class Action Lawsuit Filed: Marex Group plc (MRX) - Join by December 8, 2025 - Contact Levi & Korsinsky
A class action lawsuit has been filed against Marex Group plc (NASDAQ: MRX) alleging securities fraud between May 16, 2024, and August 5, 2025. The lawsuit claims Marex improperly inflated its cash flow, revenues, assets, and profits within its Market Making segment through off-book intercompany transactions. Shareholders who suffered losses during this period are encouraged to contact Levi & Korsinsky LLP by December 8, 2025, to learn about potential recovery options.
